Date:

RECEIVED CENTRAL FAX CENTER

TEL:9198622260

P. 001

JUL 2 9 2004



This facsimile message and its contents are legally privileged and confidential information intended solely for the use of the addressee. If the reader of this message is not the intended recipient, you are hereby notified that any dissemination, distribution, copying or other use of this message and its contents is strictly prohibited. If you have received this telecopy in error, please notify us immediately by telephone and return the original message to us at the address shown below via the Postal Service. Thank You.

ALSTON&BIRD LLP

3201 Beechleaf Court, Suite 600 Raleigh, NC 27604-1062 919-862-2200 Fax: 919-862-2260

TELECOPY

PLEASE DELIVER AS SOON AS POSSIBLE

Recipient:	Company:
Mail Stop RCE	USPTO
Fax Number:	Voice Number:
703 872 9306	
Sender:	
Leslie T. Henry	
Message:	non 10, 2001
Re: Appl. No. 09/954,764, filed Septemb	ner 18, 2001 mber of Pages: (including cover page) 26
Re: Appl. No. 09/954,764, filed Septemb	<u> </u>
Re: Appl. No. 09/954,764, filed Septemb	mber of Pages: (including cover page) 26

PAGE 2/26 * RCVD AT 7/29/2004 5:42:34 PM [Eastern Daylight Time] * SVR:USPTO-EFXRF-1/1 * DNIS:8729306 * CSID:9198622260 * DURATION (mm-55):09-52

REQUEST For CONTINUED EXAMINATION (RCE) TRANSMITTAL

Address to:
MAIL STOP RCE
COMMISSIONER FOR PATENTS
P.O. BOX 1450
ALEXANDRIA, VA 22313-1450

(Revised 09/2003)

Application Number 09/954,764
Filing Date: September 18, 2001
First Named Inventor: de Boet
Art Unit: 1644
Examiner Name: Phillip Gambel
Confirmation No.: 8879
Attorney Docket No. 925.302

This is a request for Continued Examination (RCE) under 37 C.F.R. § 1.114 of the above-identified application. Request for Continued Examination (RCE) practice under 37 CFR 1.114 does not apply to any utility or plant application filed prior to June 8, 1995, or to any design application.

RECEIVED CENTRAL FAX CENTER

1. Submission required under 37 C.F.R. § 1.114

JUL 2 9 2004

뇝.	Previously submitted. If a final Office action is outstanding, any amendments filed after the final Office action may be considered as a submission even if this box is not checked		
	i.	Consider the arguments in the Appeal Brief or I on	Reply Brief previously filed
	ii.	Other	
ъ.	\boxtimes	Enclosed	MAL
	i.	Amendment/Reply	
	ii.	Affidavits(s)/Declarations(s):	
		(a) Copy of 132 Declaration by inventor Mark de Boer, as filed in priority document U.S. Application No. 08/070,158, now U.S. Patent No. 5,677,165 (3 pages)	
	(b) Copy of Declaration by Paul B. Savereide regarding biological deposits and accompanying contracts with ATCC outlining terms of agreement for maintenance a public availability of biological deposits, as filed in priority document U.S. Applicat No. 08/070,158, now U.S. Patent No. 5,677,165 (4 pages)		
	iii. 🔲 Information Disclosure Statement (IDS)		

In re: Appl.	de Boer No.: 09/954,764 September 18, 2001	FAGE 3126 * RCVD AT 712912004 5:42:34 PM [Eastern Daylight Time] * SVR:USPTO-EF	
	99104709.3, which observations in the PTO Form 1449 accompanying	I in corresponding European Patent Application No. clude a copy of the reference listed as cite no. C9 on the Information Disclosure Statement filed March 19, cation (14 pages) submissions filed concurrently herewith (2 pages)	
2.	Miscellaneous a. Suspension of action on the above-identified application is requested under 37 C.F.R. §1.103(c) for a period of months. (Period of suspension shall not exceed 3 months; Fee under 37 C.F.R. § 1.17(i) required) b. Other		
3.	Fees The RCE fee under 37 C.F.R. § 1.17(e) is required by 37 C.F.R. § 1.114 when the RCE is filed. a. The Director is hereby authorized to charge any fee deficiencies, or credit any overpayments to Deposit Account No. 16-0605. i. RCE fee required under 37 C.F.R. § 1.17(e) (\$770.00 large entity; \$385.00 small entity) ii. Extension of Time Fee (37 C.F. R. §§ 1.136 and 1.17) iii. Other b. Check in the amount of \$enclosed		
Respectfully submitted, Leslie T. Henry Registration No. 45,714			
ALS Ban 101 Cha Tei	stomer No. 00826 STON & BIRD LLP ak of America Plaza I South Tryon Street, Suitc 4000 arlotte, NC 28280-4000 I Raleigh Office (919) 862-2200 k Raleigh Office (919) 862-2260	CERTIFICATION OF FACSIMILE TRANSMISSION 1 hereby certify that this paper is being facsimile transmitted to the Patent and Trademark Office at Fax No. (703) 872-9306 on the date shown below. 1 hereby certify that this paper is being facsimile transmitted to the Patent and Trademark Office at Fax No. (703) 872-9306 on the date shown below. 1 hereby certify that this paper is being facsimile transmitted to the Patent and Trademark Office at Fax No. (703) 872-9306 on the date shown below. 1 hereby certify that this paper is being facsimile transmitted to the Patent and Trademark Office at Fax No. (703) 872-9306 on the date shown below. 1 hereby certify that this paper is being facsimile transmitted to the Patent and Trademark Office at Fax No. (703) 872-9306 on the date shown below. 1 hereby certify that this paper is being facsimile transmitted to the Patent and Trademark Office at Fax No. (703) 872-9306 on the date shown below. 1 hereby certification of the Patent and Trademark Office at Fax No. (703) 872-9306 on the date shown below. 1 hereby certification of the Patent and Trademark Office at Fax No. (703) 872-9306 on the date shown below.	

-2-

RTA01/2159540v1

Attorney's Docket No. 925.302

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED **CENTRAL FAX CENTER**

In re:

de Boer

Confirmation No.: 8879

JUL 2 9 2004

Appl. No.: 09/954.764

Group No.:

1644

Filed:

September 18, 2001

Examiner:

Phillip Gambel

For:

METHOD FOR TREATING AN 1gE-MEDIATED DISEASE IN A PATIENT

USING ANTI-CD40 MONOCLONAL ANTIBODIES

July 29, 2004

MAIL STOP RCE Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450



COMMUNICATION

Applicants file concurrently herewith a Request for Continued Examination of the abovereferenced application under 37 C.F.R. §1.114. Applicants have received notice of an April 20, 2004 Communication from the European Patent Office regarding third party observations that were lodged in a European patent application that is related to the above-identified application. The observations are based on a prior art reference, de Boer et al. (1992) Journal of Immunological Methods 152:15-23.

The de Boer et al. (1992) reference was timely cited by Applicants in the aboveidentified application as item C9 on the PTO Form 1449 accompanying the Information Disclosure Statement filed March 19, 2002. The Examiner has already considered this reference, as evidenced by the initialed copy of this PTO Form 1449 included with the Office Action mailed September 30, 2003.

This RCE is submitted in order to have these third party observations made officially of record in this application for the sake of full disclosure. The Examiner is respectfully requested to consider these third party observations in light of the other documents submitted concurrently herewith. These documents include the following: (1) a copy of the 132 Declaration by inventor

RTA01/2159541v1

PAGE 5/26 * RCVD AT 7/29/2004 5:42:34 PM [Eastern Daylight Time] * SVR:USPTO-EFXRF-1/1 * DNIS:8729306 * CSID:9198622260 * DURATION (mm-ss):09-52

In re: de Boer

Appl. No.: 09/954,764 Filed: September 18, 2001

Page 2

Mark de Boer that was filed in priority document U.S. Application No. 08/070,158, now U.S. Patent No. 5,677,165, in response to the Examiner's rejection of the claims in that priority document in view of this same de Boer et al. (1992) reference; and (2) a copy of the Declaration by Paul B. Savereide regarding biological deposits and the accompanying contracts with ATCC outlining terms of agreement for maintenance and public availability of biological deposits, which were also filed in priority document U.S. Application No. 08/070,158. Although the entire contents of the priority document were incorporate herein by reference, Applicants submit paper copies of these two documents so that the physical contents of the above-identified application are complete when the Examiner considers these third party observations.

It is not believed that extensions of time or fees are required beyond those that may otherwise be provided for in documents accompanying this paper. However, in the event that additional extensions of time are necessary to allow consideration of this paper, such extensions are hereby petitioned under 37 CFR § 1.136(a), and any fee required therefore is hereby authorized to be charged to Deposit Account No. 16-0605.

Respectfully submitted,

Leslie T. Henry

Registration No. 45,714

Customer No. 00826 ALSTON & BIRD LLP

Bank of America Plaza 101 South Tryon Street, Suite 4000 Charlotte, NC 28280-4000 Tel Raleigh Office (919) 862-2200 Fax Raleigh Office (919) 862-2260 CERTIFICATION OF FACSIMILE TRANSMISSION

I hereby certify that this paper is being facsimile transmitted to the Patent and Trademark Office at Fax

No. (703) 872-9306 on the date shown below.

RTA01/2159541v1